Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe
Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe
复制标题
DOI：
10.1016/s1473-3099(14)70071-4
复制
发表时间：
2014-05-01
影响因子：
56.3
通讯作者：
Goossens, Herman
中科院分区：
文献类型：
--
作者：
Versporten, Ann;Bolokhovets, Ganna;Goossens, Herman
背景目前尚无关于非欧盟（EU）南欧和东欧国家以及新独立国家抗生素使用的可靠数据。我们旨在收集有效的，有代表性的，方法根据WHO解剖治疗化学（ATC）/限定日剂量（DDD）方法分析了6个南欧和东欧国家和地区以及7个新独立国家2011年经验证的全国批发抗菌药物使用总量数据，并以DDD/1000居民每天（DID）。结果总（门诊和医院护理）抗生素的使用范围从15-3 DID为亚美尼亚到42-3 DID为土耳其。Co-amoxidav主要用于格鲁吉亚（占抗生素使用总量的42.9%）和土耳其（30.7%）。新独立的国家使用大量氨苄西林和阿莫西林（占阿塞拜疆抗生素使用总量的55.9%）。黑山和塞尔维亚是大环内酯类药物的最高消费者（分别占抗生素总使用量的15-8%和19.5%），主要是阿奇霉素。肠外抗生素治疗是常见的做法：46.4%的总抗生素使用在阿塞拜疆（主要是氨苄青霉素; 5.3 DID）和31.1%的总抗生素使用在塔吉克斯坦（主要是头孢曲松; 4.7 DID）。这些数据将提高人们对抗生素不当使用的认识，并刺激政策制定者制定行动计划。已建立的监测系统为制定抗生素使用质量指标和评估政策和监管行动的效果提供了一种方法。Copyright（c）2014.世界卫生组织。出版社：Elsevier Ltd/Inc/BV All rights reserved.
Background There are no reliable data on antibiotic use in non-European Union (EU) southern and eastern European countries and newly independent states. We aimed to collect valid, representative, comparable data on systemic antimicrobial use in these non-EU countries of the WHO European region.Methods Validated 2011 total national wholesale antibiotic-use data of six southern and eastern European countries and regions and seven newly independent states were analysed in accordance with the WHO anatomical therapeutic chemical (ATC)/defined daily doses (DDD) method and expressed in DDD/1000 inhabitants per day (DID).Findings Total (outpatients and hospital care) antibiotic use ranged from 15-3 DID for Armenia to 42-3 DID for Turkey. Co-amoxidav was mainly used in Georgia (42.9% of total antibiotic use) and Turkey (30.7%). Newly independent states used substantial quantities of ampicillin and amoxicillin (up to 55.9% of total antibiotic use in Azerbaijan). Montenegro and Serbia were the highest consumers of macrolides (15-8% and 19.5% of total antibiotic use, respectively), mainly azithromydn. Parenteral antibiotic treatment is common practice: 46.4% of total antibiotic use in Azerbaijan (mainly ampicillin; 5.3 DID) and 31.1% of total antibiotic use in Tajikistan (mainly ceftriaxone; 4.7 DID).Interpretation This study provides publicly available total antibiotic-use data for 13 non-EU countries and areas of the WHO European region. These data will raise awareness of inappropriate antibiotic use and stimulate policy makers to develop action plans. The established surveillance system provides a method to develop quality indicators of antibiotic use and to assess the effect of policy and regulatory actions. Copyright (c) 2014. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved.